Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Adjuvant Nivolumab IV to Subcutaneous Switch in Resected Melanoma or Urothelial Carcinoma
2022-000294-67Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma and transitional cell carcinoma of the bladder (TCC), sponsored by Bristol Myers Squibb. Primary endpoint: Participant preference for subcutaneous nivolumab. Started Jul 2022; status: terminated.
02
Drugs
03
Conditions
melanomatransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2022-000294-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000294-67.